SG11201807991QA - Use of nucleosome-transcription factor complexes for cancer detection - Google Patents

Use of nucleosome-transcription factor complexes for cancer detection

Info

Publication number
SG11201807991QA
SG11201807991QA SG11201807991QA SG11201807991QA SG11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA
Authority
SG
Singapore
Prior art keywords
international
cancer
transcription factor
nucleosome
phocas
Prior art date
Application number
SG11201807991QA
Inventor
Jacob Vincent Micallef
Jorge Reis-Filho
Original Assignee
Belgian Volition Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55968658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201807991Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Belgian Volition Sprl filed Critical Belgian Volition Sprl
Publication of SG11201807991QA publication Critical patent/SG11201807991QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111011101111010101111011111111011110111 International Bureau ... .... ..Yjd ..... ...,/ (10) International Publication Number (43) International Publication Date WO 2017/162755 Al 28 September 2017 (28.09.2017) WIP0 I PCT — (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) (74) International Patent Classification: (81) Designated States (unless otherwise indicated, for every GO1N 33/574 (2006.01) G01N 33/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/056851 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 22 March 2017 (22.03.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Priority Data: ZA, ZM, ZW. 1604806.8 22 March 2016 (22.03.2016) GB (84) Designated States (unless otherwise indicated, for every Applicant: BELGIAN VOLITION SPRL [BE/BE]; 22 kind of regional protection available): ARIPO (BW, GH, Rue Phocas Lejeune, BE-5032 Isnes (BE). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Inventors: MICALLEF, Jacob Vincent; c/o Belgian Vo- lition SPRL, 22 Rue Phocas Lejeune, BE-5032 Isnes (BE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, REIS-FILHO, Jorge; c/o Belgian Volition SPRL, 22 Rue DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Phocas Lejeune, BE-5032 Isnes (BE). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Agents: AITKEN, Elizabeth et al.; Sagittarius IP, Three GW, KM, ML, MR, NE, SN, TD, TG). Globeside, Fieldhouse Lane, Marlow, Buckinghamshire SL7 1HZ (GB). [Continued on next page] — = Title: USE OF NUCLEOSOME-TRANSCRIPTION FACTOR COMPLEXES FOR CANCER DETECTION (54) (57) : The invention relates to the use of tissue specific transcription factor- nucleo some adducts or transcription cofactor-nucleosome adducts as biomark- ers in a biological fluid for the detection or diagnosis of a cancer in a subject. The in- vention further relates to using said tissue specific transcription factor or cofactor ad- ducts to identify the site of development of a cancer in a subject. = - _ =0,5 0,4 03 RI ca _ 0,0 0 0,2 = = _ = = — = = = = — = = Il ir) ir) IN ei ,-, IN ,-, © ei \"lay Healthy Breast Br , ?as - E-.-a , 57 lrin:r: Uro7hliat Control Cancer Cancer Cancer Bladder Carcinoma FIGURE 1 O WO 2017/162755 Al MIDEDIMOMMION1111111111111111111111111111111111110111111111110111111111111 Declarations under Rule 4.17: — before the expiration of the time limit for amending the — as to the applicant's entitlement to claim the priority the earlier application (Rule 4.17(iii)) of claims and amendments (Rule to be republished 48.2(h)) in the event of receipt of Published: — with international search report (Art. 21(3))
SG11201807991QA 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection SG11201807991QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Publications (1)

Publication Number Publication Date
SG11201807991QA true SG11201807991QA (en) 2018-10-30

Family

ID=55968658

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807991QA SG11201807991QA (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Country Status (12)

Country Link
US (1) US20200363418A1 (en)
EP (3) EP4270007A3 (en)
JP (1) JP6777757B2 (en)
KR (2) KR102369544B1 (en)
CN (1) CN109313192B (en)
AU (1) AU2017238442A1 (en)
CA (1) CA3018428C (en)
ES (2) ES2861440T3 (en)
GB (1) GB201604806D0 (en)
MY (1) MY187655A (en)
SG (1) SG11201807991QA (en)
WO (1) WO2017162755A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (en) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 Method for measurment of cell free nucleoprotein chromatin fragments
TW202242145A (en) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 Transcription factor binding site analysis of nucleosome depleted circulating cell free chromatin fragments
TW202242130A (en) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 Circulating transcription factor analysis
WO2023048509A1 (en) * 2021-09-24 2023-03-30 주식회사 온코크로스 Method for determining primary tumor site

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012931A1 (en) * 2000-03-27 2002-01-31 Waldman Scott A. High specificity marker detection
US7601684B2 (en) * 2001-09-14 2009-10-13 Roche Diagnostics Corporation Diagnosis and treatment of disorders of iron metabolism
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
MY148542A (en) * 2009-06-15 2013-04-30 Cancer Res Initiatives Foundation A method for the assessment of cancer in a biological sample obtained from a subject
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
AU2012349855B2 (en) * 2011-12-07 2017-12-07 Belgian Volition Sprl Method for detecting nucleosome adducts
GB201303576D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers

Also Published As

Publication number Publication date
EP4270007A2 (en) 2023-11-01
ES2951136T3 (en) 2023-10-18
KR20190013707A (en) 2019-02-11
US20200363418A1 (en) 2020-11-19
EP3433616B2 (en) 2024-07-24
CA3018428C (en) 2024-03-19
GB201604806D0 (en) 2016-05-04
CN109313192A (en) 2019-02-05
EP3433616A1 (en) 2019-01-30
EP3839513A1 (en) 2021-06-23
AU2017238442A1 (en) 2018-10-11
CA3018428A1 (en) 2017-09-28
KR102369544B1 (en) 2022-03-03
JP6777757B2 (en) 2020-10-28
EP3839513B1 (en) 2023-06-14
KR20210049954A (en) 2021-05-06
KR102246699B1 (en) 2021-05-04
MY187655A (en) 2021-10-07
EP3839513C0 (en) 2023-06-14
JP2019510974A (en) 2019-04-18
EP3433616B1 (en) 2020-12-30
CN109313192B (en) 2022-07-26
WO2017162755A1 (en) 2017-09-28
EP4270007A3 (en) 2023-12-20
ES2861440T3 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807991QA (en) Use of nucleosome-transcription factor complexes for cancer detection
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201808562SA (en) Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer